Introduction Syngene International Ltd. is a worldwide discovery, development, and manufacturing organization that offers comprehensive scientific services to diverse industries. The company specializes in contract research and manufacturing services, offering a range of services including discovery chemistry and biology, safety assessment, large molecule and chemical development, formulation development, stability studies, and polymer research. It also focuses on integrated discovery and development along with clinical development. Founded on November 18, 1993, the company is based in Bangalore, India. |
Disease Domain | Count |
---|---|
Nervous System Diseases | 2 |
Immune System Diseases | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Top 5 Target | Count |
---|---|
CGRP x CGRP receptor | 2 |
1,3-beta-glucan synthase | 1 |
GPR52(G protein-coupled receptor 52) | 1 |
Target |
Mechanism 1,3-beta-glucan synthase inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date01 Jun 2021 |
Target |
Mechanism GPR52 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CALCRL antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date07 Mar 2024 |
Sponsor / Collaborator |
Start Date01 Feb 2024 |
Sponsor / Collaborator |
Start Date05 May 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ibrexafungerp Citrate ( 1,3-beta-glucan synthase ) | Candidiasis, Vulvovaginal More | NDA/BLA |
HTL0029882 ( CGRP x CGRP receptor ) | Migraine Disorders More | Preclinical |
HTL-0029881 ( CGRP x CGRP receptor ) | Migraine Disorders More | Preclinical |
HTL-0041178 ( GPR52 ) | Schizophrenia More | Preclinical |
NCE-001 ( PP2A ) | Alzheimer Disease More | Discontinued |